Nkcfo LLC Raises Stock Position in Koninklijke Philips (NYSE:PHG)

Nkcfo LLC lifted its holdings in shares of Koninklijke Philips (NYSE:PHG) by 3.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,414 shares of the technology company’s stock after acquiring an additional 3,514 shares during the quarter. Koninklijke Philips comprises approximately 1.5% of Nkcfo LLC’s holdings, making the stock its 16th biggest holding. Nkcfo LLC’s holdings in Koninklijke Philips were worth $2,682,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Mondrian Investment Partners LTD grew its position in Koninklijke Philips by 45.1% in the first quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock valued at $191,061,000 after acquiring an additional 2,971,008 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Koninklijke Philips by 27.3% in the second quarter. Dimensional Fund Advisors LP now owns 4,036,336 shares of the technology company’s stock valued at $101,718,000 after purchasing an additional 864,951 shares during the period. Russell Investments Group Ltd. grew its holdings in Koninklijke Philips by 36.4% during the 1st quarter. Russell Investments Group Ltd. now owns 1,410,067 shares of the technology company’s stock valued at $28,201,000 after purchasing an additional 376,244 shares in the last quarter. Natixis Advisors LLC increased its stake in Koninklijke Philips by 5.2% during the 2nd quarter. Natixis Advisors LLC now owns 930,085 shares of the technology company’s stock worth $23,438,000 after buying an additional 46,268 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Koninklijke Philips by 16.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 917,560 shares of the technology company’s stock worth $21,407,000 after buying an additional 129,830 shares in the last quarter. 13.67% of the stock is owned by hedge funds and other institutional investors.

Koninklijke Philips Stock Performance

Koninklijke Philips stock opened at $30.58 on Friday. Koninklijke Philips has a 52 week low of $17.75 and a 52 week high of $31.50. The company has a current ratio of 1.16, a quick ratio of 0.74 and a debt-to-equity ratio of 0.60. The stock has a market cap of $28.74 billion, a P/E ratio of -31.85, a price-to-earnings-growth ratio of 1.06 and a beta of 0.73. The stock has a 50 day moving average of $28.88 and a 200-day moving average of $25.70.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings results on Monday, July 29th. The technology company reported $0.32 earnings per share (EPS) for the quarter. The firm had revenue of $4.80 billion for the quarter. Koninklijke Philips had a negative net margin of 2.35% and a positive return on equity of 10.15%. On average, analysts expect that Koninklijke Philips will post 1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.